SELDI-TOF mass spectrometry of high-density lipoprotein

被引:17
作者
Levels, Johannes H. M.
Bleijlevens, Boris
Rezaee, Farhad
Aerts, Johannes M. F. G.
Meijers, Joost C. M.
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands
[3] Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Mol Biosci, London SW7 2AZ, England
[4] Med Univ Groningen, Ctr Med Biom, NL-9713 AV Groningen, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1186/1477-5956-5-15
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: High-Density Lipoprotein ( HDL), one of the main plasma lipoproteins, serves as a docking station for proteins involved in inflammation, coagulation, and lipid metabolism. Methods: To elucidate the protein composition of HDL, we employed SELDI-TOF mass spectrometry as a potential high-throughput proteomic candidate for protein profiling of HDL. HDL derived from normolipemic individuals was captured on PS20 protein-chips using covalently bound antibodies against apo A-I or A-II. Results: After optimisation, on-chip capture of HDL particles directly from plasma or from pre-purified HDL resulted in comparable fingerprints confirming specific capture of HDL. Depending on the capture antibody some differences in the fingerprint were observed. The most detailed fingerprint was observed up to 50 kDa; approximately 95 peaks were detected in the 3 - 50 kDa molecular mass range. Between 50 and 160 kDa, 27 more peaks were detected. Conclusion: Based on these results, SELDI-TOF MS may be a suitable high-throughput candidate for HDL protein profiling and marker search. This approach may be used to i) investigate the underlying mechanisms that lead to increased atherothrombotic risk and ii) to investigate the atherothrombotic state of an individual.
引用
收藏
页数:8
相关论文
共 38 条
[1]  
AUERBACH BJ, 1989, J BIOL CHEM, V264, P10264
[2]   Antiinflammatory properties of HDL [J].
Barter, PJ ;
Nicholls, S ;
Rye, KA ;
Anantharamaiah, GM ;
Navab, M ;
Fogelman, AM .
CIRCULATION RESEARCH, 2004, 95 (08) :764-772
[3]   A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes [J].
Davidsson, P ;
Hulthe, J ;
Fagerberg, B ;
Olsson, BM ;
Hallberg, C ;
Dahllöf, B ;
Camejo, G .
JOURNAL OF LIPID RESEARCH, 2005, 46 (09) :1999-2006
[4]   ProteinChip technology: A new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease [J].
Dayal, B ;
Ertel, NH .
JOURNAL OF PROTEOME RESEARCH, 2002, 1 (04) :375-380
[5]   TANGIER DISEASE - ISOLATION AND CHARACTERIZATION OF LPA-I, LPA-II, LPA-I-A-II AND LPA-IV PARTICLES FROM PLASMA [J].
DUCHATEAU, P ;
RADER, D ;
DUVERGER, N ;
THERET, N ;
DEGEITERE, C ;
BREWER, HB ;
FRUCHART, JC ;
CASTRO, GR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1182 (01) :30-36
[6]   Classification of cancer types by measuring variants of host response proteins using SELDI serum assays [J].
Fung, ET ;
Yip, TT ;
Lomas, L ;
Wang, Z ;
Yip, C ;
Meng, XY ;
Lin, SH ;
Zhang, FJ ;
Zhang, Z ;
Chan, DW ;
Weinberger, SR .
INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (05) :783-789
[7]   LIPIDS, LIPOPROTEINS, TRIGLYCERIDE CLEARANCE, AND CYTOKINES IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
GRUNFELD, C ;
PANG, MY ;
DOERRLER, W ;
SHIGENAGA, JK ;
JENSEN, P ;
FEINGOLD, KR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (05) :1045-1052
[8]   The acute phase response in apolipoprotein A-1 knockout mice: apolipoprotein serum amyloid A and lipid distribution in plasma high density lipoproteins [J].
Hajri, T ;
Elliott-Bryant, R ;
Sipe, JD ;
Liang, JS ;
Hayes, KC ;
Cathcart, ES .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1998, 1394 (2-3) :209-218
[9]   Inflammation and immune response in atherosclerosis [J].
Hansson G.K. .
Current Atherosclerosis Reports, 1999, 1 (2) :150-155
[10]   Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins [J].
Heller, M ;
Stalder, D ;
Schlappritzi, E ;
Hayn, G ;
Matter, U ;
Haeberli, A .
PROTEOMICS, 2005, 5 (10) :2619-2630